Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

On a recent BBC World Service program (News Hour Extra, 12.18.15), a group of space scientists were gathered to discuss these and other aspects of the post-human era. “What about the human soul”, the moderator asked, wondering whether or not these post-humans would still be human. None of the participants were particularly troubled by the question, since they all had assumed that the soul was no more than the particular configurations of DNA which resulted in varying degre…es of insight, intelligence, creativity, and sensitivity. Post-humans will be no different, they all agreed. Only their individual genomes will have been altered to produce a very different human reality – in other words a different human soul.

Once the human genome was completely sequenced; once efforts to recombine DNA had become a reality; and once a mind-computer interface had been realized, there was never any doubt that a post-human era was coming.

Read more

https://www.wired.com/…/biology-will-be-the-next-great-comp…

In some ways, Synthego looks like any other Silicon Valley startup. Inside its beige business park facilities, a five-minute drive from Facebook HQ, rows of nondescript black server racks whir and blink and vent. But inside the metal shelving, the company isn’t pushing around ones and zeros to keep the internet running. It’s making molecules to rewrite the code of life.

Crispr, the powerful gene-editing tool, is revolutionizing the speed and scope with which scientists can modify the DNA of organisms, including human cells. So many people want to use it—from academic researchers to agtech companies to biopharma firms—that new companies are popping up to staunch the demand. Companies like Synthego, which is using a combination of software engineering and hardware automation to become the Amazon of genome engineering. And Inscripta, which wants to be the Apple. And Twist Bioscience, which could be the Intel.

All these analogies to the computing industry are more than just wordplay. Crispr is making biology more programmable than ever before. And the biotech execs staking their claims in Crispr’s backend systems have read their Silicon Valley history. They’re betting biology will be the next great computing platform, DNA will be the code that runs it, and Crispr will be the programming language.

Read more

A compelling study from a team of researchers at the University of Copenhagen has demonstrated a way to completely stop a body’s ability to store fat. In experiments with mice, the team showed that genetically deleting a single enzyme resulted in the animal not being able to gain weight, even when fed a fatty diet.

An enzyme dubbed NAMPT has been connected to obesity in both human and animal models by several studies. Its presence in fat tissue has been found to increase metabolic functionality in numerous body tissues, including fat tissue, which enhances the body’s ability to store fat.

“NAMPT in fat tissue was likely once an extraordinary benefit to our ancestors but in today’s society full of high-fat, calorically-dense foods, it may now pose a liability,” says Zachary Gerhart-Hines, a corresponding author on the study.

Read more

A new study published by researchers at Western University and Lawson Health Research Institute has shown a link between the gut microbiome and atherosclerosis.

During the study, the team examined blood levels of metabolic products in the gut microbiomes of 316 people from three groups: those with regular levels of plaque for their age, those who had low levels of plaque despite being at high risk, and those who had unusually high levels of plaque.

They discovered that in the patients with unusually high levels of plaque, there were significantly higher blood levels of harmful metabolic products. Specifically, these were the metabolites TMAO, p-cresyl sulfate, p-cresyl glucuronide, and phenylacetylglutamine, which are created by gut bacteria. They also assessed the development of plaques in the arteries via carotid ultrasound.

Read more

If you’re like most people, the first biological cell you ever saw was flat: a diagram in a book, or maybe a microscope image on a slide if you were lucky. Same goes for scientists. It’s hard enough to zoom in on something so small, much less capture a 3D image of the thing. As a result, it’s easy to imagine that there are a multitude of two-dimensional discs filling your blood vessels and fighting your infections. That’s why this new development is so eye-opening. Researchers have made an imaging breakthrough that lets them capture 3D footage of cells doing their thing inside the body — and it may look nothing like what you imagined.

The video below depicts the inner ear of a zebrafish — you know, that little inch-and-a-half (4-centimeter) striped thing you see in pet store fish tanks? Suffice it to say, the objects in this footage are very, very small. Here, a fiery yellow immune cell rolls on through gobbling up bright-blue particles of sugar.

Read more

A human study of the mitochondrial antioxidant MitoQ shows promise in addressing some aspects of vascular aging.

Antioxidant-based therapeutics to forestall the effects of aging have had a long history, ever since the elaboration of the free radical theory of aging by Denham Harmon in 1956. However, this long history has also had mixed results, with studies alternately showing efficacy, a lack of efficacy, or even negative health effects for some applications of antioxidants. Many of these studies analyzed the results of taking high doses of naturally occurring antioxidants. In general, high doses are necessary due to the poor bioavailability of many of these naturally occurring compounds.

The poor bioavailability of Coenzyme Q10, a naturally occurring antioxidant that is found in cells and decreases with age, spurred scientists to develop a synthetic form. This form, dubbed MitoQ, is very similar in structure to the naturally occurring form, only it has a triphenylphosphonium moiety that allows this derivative to be two to three orders of magnitude more permeable to membranes, particularly the membranes of mitochondria. It is within mitochondria that MitoQ appears to be doing most of its work by soaking up reactive molecules, generated as byproducts of respiration, that can oxidize and damage lipids and proteins.

Read more

We are delighted to announce our first US conference in NYC. An action-packed day of research and investment and the first of the events we have planned this year.

At the Frederick P. Rose Auditorium, Cooper Union in New York City, we will be hosting a special one-day conference focused on aging research and biotech investment. Developing therapies from initial concepts, through clinical testing, and ultimately to market takes a pipeline, and right now, that pipeline is being built to support the next step in medicine: rejuvenation biotechnology. Join us for this exciting event, where industry experts will be sharing their insights on the advances and investment prospects in an industry poised to revolutionize medicine forever.

Read more